TScan Therapeutics' (TCRX) "Overweight" Rating Reiterated at Morgan Stanley

TScan Therapeutics (NASDAQ:TCRX - Get Free Report)'s stock had its "overweight" rating reiterated by stock analysts at Morgan Stanley in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $10.00 price target on the stock.

A number of other equities analysts also recently issued reports on the company. HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of TScan Therapeutics in a research note on Thursday, March 6th. Wedbush reissued an "outperform" rating and set a $7.00 target price on shares of TScan Therapeutics in a research note on Wednesday, March 5th. Needham & Company LLC cut their target price on TScan Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. Finally, Barclays cut their target price on TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $9.33.

TScan Therapeutics Stock Performance

TScan Therapeutics stock traded up $0.04 during mid-day trading on Friday, reaching $1.59. 605,804 shares of the company were exchanged, compared to its average volume of 320,462. TScan Therapeutics has a twelve month low of $1.51 and a twelve month high of $9.69. The firm's 50-day simple moving average is $2.23 and its two-hundred day simple moving average is $3.80. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. The firm has a market cap of $89.98 million, a PE ratio of -1.50 and a beta of 0.91.

Remove Ads

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.02). The business had revenue of $0.67 million for the quarter, compared to analysts' expectations of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. Equities analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TScan Therapeutics

Several hedge funds have recently bought and sold shares of TCRX. China Universal Asset Management Co. Ltd. purchased a new position in TScan Therapeutics during the fourth quarter worth $32,000. Prudential Financial Inc. purchased a new position in TScan Therapeutics during the fourth quarter worth $32,000. ProShare Advisors LLC purchased a new position in TScan Therapeutics during the fourth quarter worth $40,000. Wells Fargo & Company MN increased its position in TScan Therapeutics by 41.1% during the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after buying an additional 5,694 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in TScan Therapeutics during the fourth quarter worth $59,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.